Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaochen Zhao

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
JAMA Oncology|December 27, 2019
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJianchun Duan, Longgang Cui, Xiaochen Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2020
Identification of Deleterious <i>NOTCH</i> Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLCKai Zhang, Xiaohua Hong, Zhengbo Song, et al.
Journal of Translational Medicine|January 31, 2023
Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancerZhaoya Gao, Dandan Huang, Hui Chen, et al.
Cancer Research|September 2, 2018
Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint BlockadeZhijie Wang, Jing Zhao, Guoqiang Wang, et al.
BMC Medicine|July 21, 2022
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)Sha Zhu, Jinge Zhao, Ling Nie, et al.
Nature Communications|August 14, 2023
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trialJia Wei, Xiaofeng Lu, Qin Liu, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trialWenwen Zhang, Shuang Tong, Bingyang Hu, et al.
BJU International|June 29, 2021
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostateJinge Zhao, Guangxi Sun, Sha Zhu, et al.
JAMA Oncology|March 1, 2019
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene PanelZhijie Wang, Jianchun Duan, Shangli Cai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 InhibitorsZhijie Wang, Jianchun Duan, Guoqiang Wang, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
JAMA Oncology|December 27, 2019
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJianchun Duan, Longgang Cui, Xiaochen Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2020
Identification of Deleterious <i>NOTCH</i> Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLCKai Zhang, Xiaohua Hong, Zhengbo Song, et al.
Journal of Translational Medicine|January 31, 2023
Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancerZhaoya Gao, Dandan Huang, Hui Chen, et al.
Cancer Research|September 2, 2018
Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint BlockadeZhijie Wang, Jing Zhao, Guoqiang Wang, et al.
BMC Medicine|July 21, 2022
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)Sha Zhu, Jinge Zhao, Ling Nie, et al.
Nature Communications|August 14, 2023
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trialJia Wei, Xiaofeng Lu, Qin Liu, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trialWenwen Zhang, Shuang Tong, Bingyang Hu, et al.
BJU International|June 29, 2021
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostateJinge Zhao, Guangxi Sun, Sha Zhu, et al.
JAMA Oncology|March 1, 2019
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene PanelZhijie Wang, Jianchun Duan, Shangli Cai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 InhibitorsZhijie Wang, Jianchun Duan, Guoqiang Wang, et al.
Pageof 11